Cell
Volume 173, Issue 2, 5 April 2018, Pages 321-337.e10
Journal home page for Cell

Article
Oncogenic Signaling Pathways in The Cancer Genome Atlas

https://doi.org/10.1016/j.cell.2018.03.035Get rights and content
Under a Creative Commons license
open access

Highlights

  • Alteration map of 10 signaling pathways across 9,125 samples from 33 cancer types

  • Reusable, curated pathway templates that include a catalogue of driver genes

  • 57% of tumors have at least one potentially actionable alteration in these pathways

  • Co-occurrence of actionable alterations suggests combination therapy opportunities

Summary

Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and cell growth are common hallmarks of cancer, but the extent, mechanisms, and co-occurrence of alterations in these pathways differ between individual tumors and tumor types. Using mutations, copy-number changes, mRNA expression, gene fusions and DNA methylation in 9,125 tumors profiled by The Cancer Genome Atlas (TCGA), we analyzed the mechanisms and patterns of somatic alterations in ten canonical pathways: cell cycle, Hippo, Myc, Notch, Nrf2, PI-3-Kinase/Akt, RTK-RAS, TGFβ signaling, p53 and β-catenin/Wnt. We charted the detailed landscape of pathway alterations in 33 cancer types, stratified into 64 subtypes, and identified patterns of co-occurrence and mutual exclusivity. Eighty-nine percent of tumors had at least one driver alteration in these pathways, and 57% percent of tumors had at least one alteration potentially targetable by currently available drugs. Thirty percent of tumors had multiple targetable alterations, indicating opportunities for combination therapy.

Keywords

pan-cancer
signaling pathways
whole exome sequencing
therapeutics
combination therapy
TCGA
PanCanAtlas
cancer genome atlas
cancer genomics
precision oncology

Cited by (0)

30

These authors contributed equally

31

Co-senior author

32

Lead contact